119 related articles for article (PubMed ID: 2437641)
21. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank.
Ritts RE; Del Villano BC; Go VL; Herberman RB; Klug TL; Zurawski VR
Int J Cancer; 1984 Mar; 33(3):339-45. PubMed ID: 6199316
[TBL] [Abstract][Full Text] [Related]
22. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
23. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
Neunteufel W; Breitenecker G
Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
26. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.
Andriulli A; Gindro T; Piantino P; Farini R; Cavallini G; Piazzi L; Naccarato R; Dobrilla G; Verme G; Scuro LA
Digestion; 1986; 33(1):26-33. PubMed ID: 3940235
[TBL] [Abstract][Full Text] [Related]
27. [Comparative study of 3 markers in ovarian cancer: CA 125, CA 19,9 and CEA].
Vigné E; Krebs B; Khater R; Mira R; Boublil JL; Jourlait A; Frenay M; Namer M
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(5):609-13. PubMed ID: 3463621
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma.
Mennini G; Silecchia G; Zanna C; Cucchiara G; Spadaro G; Greco E; Basoli A; Speranza V
Ital J Surg Sci; 1985; 15(1):37-43. PubMed ID: 3858272
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of carcinoembryonic antigen, gastrointestinal cancer-associated antigen and alphafetoprotein in staging and management of patients with advanced carcinoma of the stomach.
Szymendera JJ; Szawlowski AW; Nowacki MP; Kowalska M; Kaminska JA; Kozlowicz-Gudzinska I
Int J Biol Markers; 1987; 2(1):19-24. PubMed ID: 2448400
[TBL] [Abstract][Full Text] [Related]
30. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.
Benini L; Cavallini G; Zordan D; Rizzotti P; Rigo L; Brocco G; Perobelli L; Zanchetta M; Pederzoli P; Scuro LA
Pancreas; 1988; 3(1):61-6. PubMed ID: 3163149
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
[TBL] [Abstract][Full Text] [Related]
32. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis.
Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R
Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255
[TBL] [Abstract][Full Text] [Related]
33. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody CIBCHTB1 defining an epitope on carcinoembryonic antigen (CEA).
Meenakshi A; Kumar NS; Vijayshanker SG
Hum Antibodies; 2000; 9(4):223-9. PubMed ID: 11341176
[TBL] [Abstract][Full Text] [Related]
35. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA].
Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R
Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850
[TBL] [Abstract][Full Text] [Related]
37. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
Klapdor R; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
[No Abstract] [Full Text] [Related]
38. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
39. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera.
Dietel M; Arps H; Klapdor R; Müller-Hagen S; Sieck M; Hoffmann L
J Cancer Res Clin Oncol; 1986; 111(3):257-65. PubMed ID: 3460995
[TBL] [Abstract][Full Text] [Related]
40. Recent progress in the immunological monitoring of carcinomas using monoclonal antibodies.
Papsidero LD
Semin Surg Oncol; 1985; 1(4):171-81. PubMed ID: 2418482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
